A detailed history of Marshall Wace, LLP transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 860,934 shares of CPRX stock, worth $18.3 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
860,934
Previous 1,219,537 29.4%
Holding current value
$18.3 Million
Previous $18.9 Million 9.4%
% of portfolio
0.02%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$15.19 - $21.35 $5.45 Million - $7.66 Million
-358,603 Reduced 29.4%
860,934 $17.1 Million
Q2 2024

Aug 14, 2024

SELL
$14.68 - $16.92 $6.82 Million - $7.86 Million
-464,414 Reduced 27.58%
1,219,537 $18.9 Million
Q1 2024

May 15, 2024

BUY
$13.18 - $17.11 $22.2 Million - $28.8 Million
1,683,951 New
1,683,951 $26.8 Million
Q3 2023

Nov 14, 2023

SELL
$11.69 - $15.02 $1.4 Million - $1.8 Million
-120,012 Reduced 61.86%
73,991 $864,000
Q2 2023

Aug 14, 2023

BUY
$11.5 - $18.08 $2.23 Million - $3.51 Million
194,003 New
194,003 $2.61 Million
Q1 2022

May 16, 2022

SELL
$5.31 - $8.31 $1.06 Million - $1.66 Million
-200,308 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$5.21 - $7.45 $1.04 Million - $1.49 Million
200,308 New
200,308 $1.36 Million
Q2 2021

Aug 13, 2021

SELL
$4.29 - $6.05 $443,294 - $625,158
-103,332 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$3.45 - $4.69 $132,707 - $180,405
-38,466 Reduced 27.13%
103,332 $476,000
Q4 2020

Feb 16, 2021

SELL
$2.97 - $3.83 $460,890 - $594,347
-155,182 Reduced 52.25%
141,798 $474,000
Q3 2020

Nov 16, 2020

SELL
$2.97 - $5.08 $96,376 - $164,846
-32,450 Reduced 9.85%
296,980 $882,000
Q2 2020

Aug 13, 2020

SELL
$3.48 - $5.05 $2.7 Million - $3.92 Million
-775,996 Reduced 70.2%
329,430 $1.52 Million
Q1 2020

May 15, 2020

SELL
$2.61 - $5.21 $1.21 Million - $2.41 Million
-462,138 Reduced 29.48%
1,105,426 $4.26 Million
Q4 2019

Feb 14, 2020

BUY
$3.67 - $5.7 $5.75 Million - $8.94 Million
1,567,564 New
1,567,564 $5.88 Million

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.19B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.